MRO Tracker · Pharma
Who can sell which medicine in India, and from when. For 50 widely used, newly opened and soon to open molecules, this tracker shows the originator, the Indian patent position, which Indian companies make generics or biosimilars, whether the price is controlled, the approved uses, common side effects and the main trials behind each drug.
Download this tracker as Excel
Semaglutide
- India status
- Generics launched
- India timeline
- Indian patent expired on 20 March 2026. Natco launched on day one at Rs 1,290 a month for multi dose vials.
- Indian makers
- Natco (with Eris marketing Sundae), Sun Pharma, Dr Reddy's, Zydus (Semaglyn, Mashema), Glenmark (Glipiq), Mankind (Samakind), Alkem, Torrent
- Price control (NLEM 2022)
- No
- Approved uses
- Type 2 diabetes; weight management (Wegovy)
- Common side effects
- Nausea, vomiting, diarrhoea, stomach pain, constipation. Label warnings on thyroid C cell tumours and pancreatitis.
- Evidence base
- SUSTAIN (diabetes), STEP (obesity), SELECT (heart outcomes)
Tirzepatide
- India status
- Patent protected
- India timeline
- Lilly launched Mounjaro vials on 20 March 2025. CDSCO approved the KwikPen in June 2025 and it reached pharmacies nationwide in August 2025. Cipla launched Yurpeak on 10 December 2025.
- Indian makers
- None. Cipla markets Lilly made Yurpeak.
- Price control (NLEM 2022)
- No
- Approved uses
- Type 2 diabetes; chronic weight management
- Common side effects
- Nausea, diarrhoea, vomiting, constipation, reduced appetite. Label warning on thyroid C cell tumours.
- Evidence base
- SURPASS (diabetes), SURMOUNT (obesity)
Liraglutide
- India status
- Generic approved
- India timeline
- Biocon received CDSCO approval for its generic in June 2025 under the 101 route, which recognises approvals from reference regulators.
- Indian makers
- Biocon (drug substance and product), launching through commercial partners
- Price control (NLEM 2022)
- No
- Approved uses
- Type 2 diabetes in adults and children aged 10 and above
- Common side effects
- Nausea, diarrhoea, vomiting, reduced appetite. Label warning on thyroid C cell tumours.
- Evidence base
- LEADER (heart outcomes), LEAD programme
Empagliflozin
- India status
- Generics launched
- India timeline
- Indian patent expired on 11 March 2025. Generic launches began the next day at prices about 80 to 90% below the brand.
- Indian makers
- Mankind (Empaglyde), Glenmark (Glempa), Alkem (Empanorm), USV (Xenia) and others; Torrent bought three Boehringer diabetes brands in December 2024
- Price control (NLEM 2022)
- No
- Approved uses
- Type 2 diabetes, heart failure, chronic kidney disease
- Common side effects
- Genital fungal infections, urinary tract infections, dehydration. Rare ketoacidosis.
- Evidence base
- EMPA-REG OUTCOME, EMPEROR-Reduced and EMPEROR-Preserved, EMPA-KIDNEY
Dapagliflozin
- India status
- Generics launched
- India timeline
- Genus patent IN 205147 expired on 2 October 2020. Zydus launched Dapaglyn on 4 October 2020 at about one third of the brand price. AstraZeneca sued over a second patent valid to 15 May 2023, and the Delhi High Court refused it an interim injunction.
- Indian makers
- Zydus (Dapaglyn), Natco (Dapnat), Alkem, USV, Eris, Torrent, Intas, MSN, Micro Labs and others
- Price control (NLEM 2022)
- No
- Approved uses
- Type 2 diabetes, heart failure, chronic kidney disease
- Common side effects
- Genital fungal infections, urinary tract infections, dehydration. Rare ketoacidosis.
- Evidence base
- DECLARE-TIMI 58, DAPA-HF, DAPA-CKD
Sitagliptin
- India status
- Generics launched
- India timeline
- Patent expired in July 2022. Glenmark launched Sitazit on 7 July 2022 at Rs 10.50 to Rs 19.90 a tablet, about one third of the brand price.
- Indian makers
- Glenmark (Sitazit) first; close to 200 brands followed
- Price control (NLEM 2022)
- No
- Approved uses
- Type 2 diabetes
- Common side effects
- Upper respiratory infection, headache. Rare pancreatitis.
- Evidence base
- TECOS (heart safety)
Vildagliptin
- India status
- Generics launched
- India timeline
- Product patent IN 212815 expired on 9 December 2019. Generic launches followed within two days.
- Indian makers
- Zydus (Vinglyn, Rs 4.95 a tablet, about one sixth of the original price), Panacea Biotec (ViLACT) and others
- Price control (NLEM 2022)
- No
- Approved uses
- Type 2 diabetes
- Common side effects
- Headache, dizziness, tremor. Liver enzyme rise; label advises liver tests.
- Evidence base
- VERIFY (early combination with metformin)
Linagliptin
- India status
- Generics launched
- India timeline
- Indian patent IN 243301 expired on 18 August 2023. In 2022 courts restrained four companies that had launched early. About 63 generic brands launched after expiry.
- Indian makers
- About 63 brands after expiry; Eris, MSN, Emcure and Optimus had launched in 2022 before expiry and were restrained
- Price control (NLEM 2022)
- No
- Approved uses
- Type 2 diabetes, including patients with kidney disease
- Common side effects
- Common cold symptoms, low blood sugar when used with sulfonylureas. Rare pancreatitis.
- Evidence base
- CARMELINA, CAROLINA (heart and kidney safety)
Teneligliptin
- India status
- Generics launched
- India timeline
- Glenmark launched in India in July 2015 after local trials, at Rs 19.90 a tablet. Mankind launched Dynaglipt on 23 November 2015 and halved its price within a day. Within about a year, 30 companies sold 34 brands.
- Indian makers
- Glenmark (Ziten, Zita Plus), Mankind (Dynaglipt), Zydus, Eris, Intas and others
- Price control (NLEM 2022)
- Yes, 20 mg tablet
- Approved uses
- Type 2 diabetes
- Common side effects
- Low blood sugar when combined with sulfonylureas or insulin.
- Evidence base
- Indian trial in 237 patients across 36 centres
Sacubitril + valsartan
- India status
- Generics launched
- India timeline
- Combination patents expired on 16 January 2023, and Glenmark launched Sacu V on 17 January 2023 at Rs 19 to Rs 45 a tablet. On 12 September 2025 the Patent Office revoked a later Novartis patent (IN 414518) on a supramolecular form.
- Indian makers
- Glenmark (Sacu V), Lupin (Valentas, Arnipin) and others; Natco, Torrent, MSN and Eris cleared to sell after the 2025 revocation
- Price control (NLEM 2022)
- No
- Approved uses
- Chronic heart failure with reduced ejection fraction
- Common side effects
- Low blood pressure, high potassium, reduced kidney function, angioedema. Not for use in pregnancy.
- Evidence base
- PARADIGM-HF
Insulin glargine
- India status
- Biosimilars launched
- India timeline
- Wockhardt launched Glaritus in March 2009 and Biocon launched Basalog on 29 May 2009. Biocon added a prefilled pen, Basalog One, in September 2015.
- Indian makers
- Biocon (Basalog); Wockhardt (Glaritus)
- Price control (NLEM 2022)
- Yes, 100 IU/mL injection
- Approved uses
- Type 1 and type 2 diabetes (long acting basal insulin)
- Common side effects
- Low blood sugar, weight gain, injection site reactions.
- Evidence base
- Biocon's Indian studies; its glargine later won the first US interchangeable biosimilar approval (2021)
Trastuzumab
- India status
- Biosimilars launched
- India timeline
- DCGI approved Biocon's biosimilar on 26 November 2013, the first biosimilar trastuzumab approved anywhere. It launched as CANMAb in February 2014.
- Indian makers
- Biocon (CANMAb) and Mylan, now Viatris (Hertraz), from the same joint development
- Price control (NLEM 2022)
- Yes, 440 mg/50 mL injection
- Approved uses
- HER2 positive breast cancer
- Common side effects
- Reduced heart function, infusion reactions, harm to the unborn baby.
- Evidence base
- Indian multi centre trial; global HERITAGE study
Adalimumab
- India status
- Biosimilars launched
- India timeline
- Zydus launched Exemptia on 9 December 2014, the first adalimumab biosimilar anywhere, at about one fifth of the originator price.
- Indian makers
- Zydus (Exemptia)
- Price control (NLEM 2022)
- No
- Approved uses
- Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis
- Common side effects
- Serious infections including TB reactivation, injection site reactions.
- Evidence base
- Zydus Phase III in India
Bevacizumab
- India status
- Biosimilars launched
- India timeline
- Reliance Life Sciences announced DCGI approval on 10 June 2016 and launched Bevacirel with Lupin; Hetero announced Cizumab on 27 June 2016.
- Indian makers
- Reliance Life Sciences with Lupin, Hetero
- Price control (NLEM 2022)
- No
- Approved uses
- Metastatic colorectal cancer (first approved use)
- Common side effects
- High blood pressure, bleeding, gut perforation, slow wound healing, protein in urine.
- Evidence base
- Indian approvals based on comparative trials
Ranibizumab
- India status
- Biosimilars launched
- India timeline
- Intas launched Razumab on 19 June 2015, the first ranibizumab biosimilar anywhere, about 25% cheaper than Lucentis.
- Indian makers
- Intas (Razumab) and others; India has five approved ranibizumab biosimilars
- Price control (NLEM 2022)
- No
- Approved uses
- Wet age related macular degeneration, diabetic macular oedema, macular oedema after vein occlusion
- Common side effects
- Eye pain, raised eye pressure, bleeding on the eye surface. Rare serious eye infection.
- Evidence base
- Head to head trial against Lucentis in Indian patients
Denosumab
- India status
- Biosimilars launched
- India timeline
- Enzene (Alkem) received DCGI approval in August 2021. Zydus launched Zyrifa (120 mg) on 10 December 2025 at an MRP of Rs 12,495.
- Indian makers
- Enzene (Alkem), Zydus; a CDSCO panel accepted Intas's Phase I report in June 2025; CuraTeQ Biologics recommended for manufacture and marketing (60 mg) in November 2026
- Price control (NLEM 2022)
- No
- Approved uses
- Osteoporosis; preventing bone complications from cancer that has spread to bone
- Common side effects
- Low calcium, jaw bone damage (rare), back and limb pain. Fracture risk can rise after stopping.
- Evidence base
- Enzene’s Indian trial; Intas Phase I in healthy volunteers
Nivolumab
- India status
- Biosimilars launched
- India timeline
- Zydus got CDSCO approval in July 2024. The Delhi High Court lifted an injunction on 12 January 2026; Zydus launched Tishtha on 22 January 2026 (100 mg at Rs 28,950). The Supreme Court dismissed BMS's petition on 11 February 2026. The Indian patent expired on 2 May 2026.
- Indian makers
- Zydus (Tishtha)
- Price control (NLEM 2022)
- No
- Approved uses
- Several cancers including melanoma, lung and kidney cancer
- Common side effects
- Immune related inflammation of lungs, gut, liver, thyroid and skin; tiredness.
- Evidence base
- CheckMate programme
Pembrolizumab
- India status
- Patent protected
- India timeline
- No biosimilar approved in India yet. The Indian patent runs to 2028. CDSCO expert panels cleared biosimilar trials by several Indian firms in 2025 and 2026.
- Indian makers
- Enzene, Hetero, Intas and Sun Pharma running Indian trials; Shilpa Biologicals and Zydus (ZRC 3323) filed trial protocols in October 2026; Zydus partner Formycon's FYB206 filing accepted for US FDA review in October 2026
- Price control (NLEM 2022)
- No
- Approved uses
- Many cancers including lung, melanoma, head and neck
- Common side effects
- Immune related inflammation of lungs, gut, liver, thyroid and skin; tiredness.
- Evidence base
- KEYNOTE programme
Osimertinib
- India status
- Patent protected
- India timeline
- Indian patent IN 297581 runs to 2032. AstraZeneca won post grant oppositions by Natco and Sunshine Organics, and the Delhi High Court granted it a permanent injunction against an infringer.
- Indian makers
- None on the market; generic attempts restrained
- Price control (NLEM 2022)
- No
- Approved uses
- EGFR mutated non small cell lung cancer
- Common side effects
- Diarrhoea, rash, dry skin, nail changes. Rare lung inflammation and heart rhythm changes.
- Evidence base
- FLAURA, ADAURA
Bedaquiline
- India status
- Off patent
- India timeline
- Used in India's TB programme since 21 March 2016. The primary patent expired in July 2023. The Patent Office rejected a secondary patent in March 2023.
- Indian makers
- Lupin (WHO prequalified 100 mg tablet, December 2023)
- Price control (NLEM 2022)
- Yes, 100 mg tablet
- Approved uses
- Drug resistant tuberculosis, with other TB medicines
- Common side effects
- Nausea, joint pain, headache. Heart rhythm (QT) changes and liver enzyme rise.
- Evidence base
- C208 trial
Sofosbuvir
- India status
- Generics launched
- India timeline
- Gilead licensed Indian makers from September 2014. DCGI approved Natco and Hetero versions on 12 March 2015, each at Rs 19,900 for 28 tablets.
- Indian makers
- Natco (Hepcinat), Hetero (Sofovir), Cipla, Zydus, Mylan, Strides and other licensees
- Price control (NLEM 2022)
- Yes, 400 mg tablet
- Approved uses
- Chronic hepatitis C, with other antivirals
- Common side effects
- Tiredness, headache, nausea. Slow heart rate if taken with amiodarone; hepatitis B can flare.
- Evidence base
- NEUTRINO, FISSION
Palbociclib
- India status
- Generics launched
- India timeline
- Indian patent expired on 10 January 2023. Sun Pharma launched the first generic on 11 January 2023. Generics cost about Rs 3,800 a month against over Rs 80,000 for the brand.
- Indian makers
- Sun Pharma (Paleno) first, BDR Pharma (BDPALBO); about 15 Indian companies producing or preparing
- Price control (NLEM 2022)
- No
- Approved uses
- HR positive, HER2 negative advanced breast cancer, with hormone therapy
- Common side effects
- Low white cell counts, infections, tiredness, nausea, hair thinning.
- Evidence base
- PALOMA trials
Ruxolitinib
- India status
- Patent protected
- India timeline
- Jakavi was launched in India in 2013. Patent IN 269841 expires on 12 December 2026. On 24 September 2026 the Delhi High Court restrained Melody Healthcare from making or selling ruxolitinib, with the next hearing on 20 January 2027.
- Indian makers
- None on sale yet. Shilpa Medicare, Aurore Life Sciences and Melody Healthcare are under court orders not to sell before expiry.
- Price control (NLEM 2022)
- No
- Approved uses
- Myelofibrosis, polycythaemia vera, graft versus host disease
- Common side effects
- Low platelet count, anaemia, bruising, dizziness
- Evidence base
- COMFORT-I, COMFORT-II
Ibrutinib
- India status
- Patent protected
- India timeline
- Patent IN 262968 runs into 2026. In December 2023 the Delhi High Court restrained six Indian companies from selling ibrutinib, and Emcure gave the court an undertaking on 13 May 2025.
- Indian makers
- None on sale yet. Natco, Hetero, BDR, Shilpa, Alkem and Laurus are restrained; Emcure has given an undertaking.
- Price control (NLEM 2022)
- No
- Approved uses
- Chronic lymphocytic leukaemia, mantle cell lymphoma, Waldenström macroglobulinaemia
- Common side effects
- Bleeding, atrial fibrillation, diarrhoea, infections
- Evidence base
- RESONATE, RESONATE-2
Dabrafenib
- India status
- Patent protected
- India timeline
- The Indian patent runs to 4 May 2029. In August 2026 the Delhi High Court passed a decree based on an undertaking by Zydus.
- Indian makers
- None on sale. Zydus has undertaken not to launch while the patent is in force.
- Price control (NLEM 2022)
- No
- Approved uses
- BRAF V600 mutant melanoma and lung cancer, usually with trametinib
- Common side effects
- Fever, rash, tiredness, joint pain
- Evidence base
- COMBI-d, COMBI-v, COMBI-AD
Netupitant + palonosetron
- India status
- Patent protected
- India timeline
- The patent was granted on 23 March 2023 and is valid to 18 November 2030. An earlier challenge by Zydus was dismissed, and Intas was restrained in November 2026.
- Indian makers
- None on sale. Intas is restrained; Zydus lost its challenge.
- Price control (NLEM 2022)
- No
- Approved uses
- Preventing nausea and vomiting from cancer chemotherapy
- Common side effects
- Headache, constipation, tiredness
- Evidence base
- Phase III trials in cisplatin and anthracycline based chemotherapy
Risdiplam
- India status
- Generics launched
- India timeline
- Patent IN 334397 runs to 11 May 2035. In March 2025 the Delhi High Court refused Roche an interim injunction against Natco. Roche lost its appeal and the Supreme Court upheld the ruling.
- Indian makers
- Natco
- Price control (NLEM 2022)
- No
- Approved uses
- Spinal muscular atrophy
- Common side effects
- Fever, diarrhoea, rash
- Evidence base
- FIREFISH, SUNFISH
Ribociclib
- India status
- Patent protected
- India timeline
- A second Indian patent was granted in 2026 after a 15 year delay. Natco filed to revoke it in August 2026. On 28 September 2026 the Kerala High Court ruled on government use of the patent under Section 100 of the Patents Act.
- Indian makers
- None on sale. Natco is challenging the patent.
- Price control (NLEM 2022)
- No
- Approved uses
- HR positive, HER2 negative breast cancer
- Common side effects
- Low white cell count, nausea, QT prolongation, raised liver enzymes
- Evidence base
- MONALEESA-2, MONALEESA-3, MONALEESA-7, NATALEE
Vericiguat
- India status
- Patent protected
- India timeline
- Patent IN 316570. Bayer won an interim injunction from the Delhi High Court in October 2026.
- Indian makers
- None on sale.
- Price control (NLEM 2022)
- No
- Approved uses
- Chronic heart failure with reduced ejection fraction after a recent worsening
- Common side effects
- Low blood pressure, anaemia
- Evidence base
- VICTORIA
Apixaban
- India status
- Off patent
- India timeline
- Patent IN 247381 expired on 17 September 2022. Before expiry the Delhi High Court restrained Cipla and Micro Labs from launching, and recorded a settlement with Indoco.
- Indian makers
- Cipla, Natco (Apigat), Micro Labs (Apivas), BDR and Indoco were all in court before expiry.
- Price control (NLEM 2022)
- No
- Approved uses
- Stroke prevention in atrial fibrillation, treating and preventing deep vein thrombosis and pulmonary embolism
- Common side effects
- Bleeding, anaemia, nausea
- Evidence base
- ARISTOTLE, AMPLIFY
Rivaroxaban
- India status
- Generics launched
- India timeline
- More than half a dozen generic rivaroxaban brands are on sale in India, many priced more than 50% below Xarelto.
- Indian makers
- Zydus, plus several other Indian brands
- Price control (NLEM 2022)
- No
- Approved uses
- Stroke prevention in atrial fibrillation, deep vein thrombosis and pulmonary embolism, coronary and peripheral artery disease with aspirin
- Common side effects
- Bleeding, anaemia
- Evidence base
- ROCKET AF, EINSTEIN DVT and PE, COMPASS
Sorafenib
- India status
- Generics launched
- India timeline
- Bayer got an Indian patent in 2008. On 9 March 2012 the Controller of Patents granted Natco India’s first compulsory licence, capping its price at Rs 8,800 for a month’s 120 tablets against Bayer’s Rs 2.8 lakh, with a 6% royalty to Bayer. The Supreme Court dismissed Bayer’s challenge in December 2014. The patent ran to 2020.
- Indian makers
- Natco (Sorafenat), Cipla (Soranib)
- Price control (NLEM 2022)
- No
- Approved uses
- Advanced kidney, liver and thyroid cancer
- Common side effects
- Hand and foot skin reaction, diarrhoea, high blood pressure, tiredness
- Evidence base
- SHARP, TARGET
Regorafenib
- India status
- Generics launched
- India timeline
- The genus patent covering regorafenib expired on 12 January 2020. Bayer sued Natco on a later patent, and in July 2023 the Delhi High Court refused an interim injunction, noting that Bayer imported the drug at Rs 36,995 while Natco made it in India and sold it at Rs 9,900.
- Indian makers
- Natco (Regonat)
- Price control (NLEM 2022)
- No
- Approved uses
- Metastatic colorectal cancer, gastrointestinal stromal tumour, liver cancer
- Common side effects
- Hand and foot skin reaction, tiredness, high blood pressure, liver injury
- Evidence base
- CORRECT, GRID, RESORCE
Enzalutamide
- India status
- Generics launched
- India timeline
- On 8 November 2016 the Indian Patent Office refused the patent after pre grant oppositions by BDR, Fresenius Kabi and others. Astellas was then selling a month’s pack of 112 capsules at Rs 3.35 lakh. Zydus launched a generic at a 70% to 90% discount, and BDR later launched 80 mg tablets at Rs 24,480 a pack.
- Indian makers
- Zydus, BDR
- Price control (NLEM 2022)
- No
- Approved uses
- Prostate cancer, castration resistant and hormone sensitive
- Common side effects
- Tiredness, hot flushes, high blood pressure, falls; seizures are rare
- Evidence base
- AFFIRM, PREVAIL, ARCHES
Olaparib
- India status
- Generics launched
- India timeline
- Patent IN 228720 was granted on 10 February 2009. The Delhi High Court permanently restrained Dr Reddy’s on 22 December 2023 and stopped Natco’s Bracanat on 1 March 2024. Zydus launched a generic in March 2024 and capped a year of treatment at Rs 3 lakh, against about Rs 72 lakh for the originator.
- Indian makers
- Zydus; Natco (Bracanat) and BDR (BDPARP) sold earlier and faced court action
- Price control (NLEM 2022)
- No
- Approved uses
- Ovarian, breast, pancreatic and prostate cancer with BRCA or related mutations
- Common side effects
- Anaemia, nausea, tiredness, vomiting
- Evidence base
- SOLO-1, OlympiAD, POLO, PROfound
Lenvatinib
- India status
- Generics launched
- India timeline
- Shilpa Medicare won approval and launched Lenshil in February 2020 at over 50% below the originator, whose average therapy cost was about Rs 1.90 lakh. BDR launched Bdfoie in October 2020 at Rs 1,620 for ten 4 mg capsules and Rs 2,970 for ten 10 mg capsules. Shilpa was later first in India with 12, 18 and 24 mg strengths.
- Indian makers
- Shilpa Medicare (Lenshil), BDR (Bdfoie)
- Price control (NLEM 2022)
- No
- Approved uses
- Thyroid, liver and kidney cancer; endometrial cancer with pembrolizumab
- Common side effects
- High blood pressure, diarrhoea, tiredness, protein in urine
- Evidence base
- SELECT, REFLECT, CLEAR
Pertuzumab
- India status
- Biosimilars launched
- India timeline
- Zydus got conditional approval for its biosimilar on 4 April 2024 and permission to market on 27 June 2024, but the Delhi High Court temporarily restrained its sale on 9 July 2024 on Roche’s patents IN 268632 and IN 464646. Intas’s biosimilar was approved in December 2024. Enzene launched on 22 September 2025, sold by Alkem and Hetero.
- Indian makers
- Enzene (sold as Alkem Pertuza and Hetero Perzea), Intas; Zydus (Sigrima) and Dr Reddy’s (Womab) under the 2024 restraint
- Price control (NLEM 2022)
- No
- Approved uses
- HER2 positive breast cancer, with trastuzumab
- Common side effects
- Diarrhoea, hair loss, low white cell count, rash
- Evidence base
- CLEOPATRA, APHINITY, NeoSphere
Aflibercept
- India status
- Biosimilars launched
- India timeline
- Biocon’s biosimilar was recommended by the expert committee in September 2025. Zydus launched Anyra, the first aflibercept 2 mg biosimilar developed in India, on 19 February 2026 under a licence from Regeneron and Bayer. In April 2026 Bayer cut the Eylea price by about 44%, from Rs 53,141 to Rs 29,998.
- Indian makers
- Zydus (Anyra), Biocon (Yesafili, recommended)
- Price control (NLEM 2022)
- No
- Approved uses
- Wet age related macular degeneration, diabetic macular oedema, macular oedema after retinal vein occlusion, diabetic retinopathy, myopic choroidal neovascularisation
- Common side effects
- Eye pain, bleeding on the eye surface, raised eye pressure; eye infection is rare
- Evidence base
- VIEW 1, VIEW 2, VIVID, VISTA
Tenofovir alafenamide
- India status
- Generics launched
- India timeline
- In July 2014 Gilead licensed tenofovir alafenamide through the Medicines Patent Pool so that makers in India and China could produce it. Mylan launched HepBest on 7 December 2017, and Natco launched Tafnat on 18 December 2017 at Rs 1,900 for 30 tablets, made under licence.
- Indian makers
- Mylan (HepBest), Natco (Tafnat)
- Price control (NLEM 2022)
- Yes
- Approved uses
- Chronic hepatitis B; part of HIV combinations
- Common side effects
- Headache, nausea, tiredness
- Evidence base
- Studies 108 and 110
Dolutegravir
- India status
- Generics launched
- India timeline
- People living with HIV filed oppositions to ViiV’s Indian patent applications in February 2016. Generic dolutegravir became available in India in February 2017 under voluntary licences from ViiV and the Medicines Patent Pool. NLEM 2022 added it as one of four patented medicines on the list.
- Indian makers
- Indian licensees of ViiV and the Medicines Patent Pool
- Price control (NLEM 2022)
- Yes
- Approved uses
- HIV infection, with other antiretrovirals
- Common side effects
- Sleep problems, headache, weight gain
- Evidence base
- SPRING-2, SINGLE, FLAMINGO
Daclatasvir
- India status
- Generics launched
- India timeline
- BMS licensed daclatasvir royalty free through the Medicines Patent Pool in November 2015. Natco became the first Indian company with DCGI approval on 14 December 2015 and launched Natdac at Rs 6,000 for 28 tablets of 60 mg and Rs 4,000 for 30 mg. Hetero was approved the same month. It is on NLEM 2022 as a patented medicine.
- Indian makers
- Natco (Natdac), Hetero, Cipla, Mylan, Zydus
- Price control (NLEM 2022)
- Yes
- Approved uses
- Chronic hepatitis C, with sofosbuvir
- Common side effects
- Headache, tiredness, nausea; slow heart rate if taken with amiodarone
- Evidence base
- ALLY-3, AI444-040
Rituximab
- India status
- Biosimilars launched
- India timeline
- Dr Reddy’s launched Reditux on 30 April 2007, the first rituximab biosimilar anywhere, at about half the originator price. Intas, Hetero (Maball) and Cadila Pharmaceuticals (Ritucad) followed. Rituximab is under price control through the essential medicines list.
- Indian makers
- Dr Reddy’s (Reditux), Intas (Mabtas), Hetero (Maball), Cadila Pharmaceuticals (Ritucad)
- Price control (NLEM 2022)
- Yes
- Approved uses
- Non Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis
- Common side effects
- Infusion reactions, infections, low white cell count; hepatitis B can flare
- Evidence base
- CLL8, REFLEX
Trastuzumab emtansine
- India status
- Biosimilars launched
- India timeline
- Zydus launched Ujvira on 24 May 2021, the first biosimilar of trastuzumab emtansine anywhere, at Rs 32,495 for a 100 mg vial against Rs 1,59,225 for the originator.
- Indian makers
- Zydus (Ujvira)
- Price control (NLEM 2022)
- No
- Approved uses
- HER2 positive breast cancer, after trastuzumab or with residual disease after surgery
- Common side effects
- Low platelet count, raised liver enzymes, tiredness, nerve damage
- Evidence base
- EMILIA, KATHERINE
Etanercept
- India status
- Biosimilars launched
- India timeline
- Cipla launched Etacept on 17 April 2013, made by Shanghai CP Guojian, at about 30% below Enbrel. Intas launched Intacept on 27 March 2015, the first etanercept made in India, at about half the price of imported Enbrel.
- Indian makers
- Cipla (Etacept), Intas (Intacept)
- Price control (NLEM 2022)
- No
- Approved uses
- Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, juvenile arthritis, plaque psoriasis
- Common side effects
- Injection site reactions, infections, reactivation of tuberculosis
- Evidence base
- TEMPO, COMET
Darbepoetin alfa
- India status
- Biosimilars launched
- India timeline
- Dr Reddy’s launched Cresp on 9 August 2010, the first darbepoetin alfa biosimilar anywhere, and said patients switching from Aranesp could save up to 85%. Hetero launched its own version in June 2014.
- Indian makers
- Dr Reddy’s (Cresp), Hetero
- Price control (NLEM 2022)
- No
- Approved uses
- Anaemia from chronic kidney disease and from chemotherapy
- Common side effects
- High blood pressure, blood clots, headache
- Evidence base
- TREAT
Pegfilgrastim
- India status
- Biosimilars launched
- India timeline
- Intas won Indian approval for Neupeg in August 2007, the first pegfilgrastim biosimilar in India. Dr Reddy’s Peg-grafeel was approved in May 2010 and Lupin’s version in September 2013.
- Indian makers
- Intas (Neupeg), Dr Reddy’s (Peg-grafeel), Lupin
- Price control (NLEM 2022)
- No
- Approved uses
- Reducing infection risk from low white cell counts during chemotherapy
- Common side effects
- Bone pain, injection site pain; spleen rupture is rare
- Evidence base
- Phase III trials against daily filgrastim
Teriparatide
- India status
- Biosimilars launched
- India timeline
- Intas was approved in November 2010, followed by Cadila Healthcare and USV in August 2012. Cadila Pharmaceuticals launched NuPTH in October 2020, and Enzene won approval on 4 February 2021, sold through Alkem.
- Indian makers
- Intas, Zydus, USV, Cadila Pharmaceuticals (NuPTH), Enzene with Alkem
- Price control (NLEM 2022)
- No
- Approved uses
- Osteoporosis with high fracture risk
- Common side effects
- Nausea, dizziness, leg cramps, raised calcium
- Evidence base
- Fracture Prevention Trial, VERO
Insulin aspart
- India status
- Biosimilars launched
- India timeline
- USV and Biogenomics launched Insuquick in November 2023, the first insulin aspart biosimilar in India. Wockhardt filed its own aspart with the DCGI in October 2024, when the Indian aspart market was over Rs 260 crore with only two players.
- Indian makers
- USV (Insuquick, with Biogenomics); Wockhardt filed
- Price control (NLEM 2022)
- No
- Approved uses
- Mealtime insulin for type 1 and type 2 diabetes
- Common side effects
- Low blood sugar, injection site reactions, weight gain
- Evidence base
- Phase III trials against regular human insulin
Tofacitinib
- India status
- Generics launched
- India timeline
- The Indian Patent Office rejected Pfizer’s patent application in 2011 and rejected it again later. Generic tofacitinib was in wide use for rheumatoid arthritis in India by 2021.
- Indian makers
- Cipla (Tofajak), MSN (Tofadoz)
- Price control (NLEM 2022)
- No
- Approved uses
- Rheumatoid arthritis, psoriatic arthritis, ulcerative colitis
- Common side effects
- Infections, shingles, raised cholesterol, blood clots
- Evidence base
- ORAL Standard, ORAL Surveillance
Ticagrelor
- India status
- Generics launched
- India timeline
- The DCGI approved Brilinta in May 2012 and AstraZeneca launched it in October 2012. AstraZeneca later sued MSN over its Tiare brand on patents IN 209907, IN 247984 and IN 272674, and the Delhi High Court lifted restraining orders on Micro Labs, Dr Reddy’s and Natco after finding a credible challenge to the patents.
- Indian makers
- MSN (Tiare), Torrent (Torplat), USV (Ticaspan)
- Price control (NLEM 2022)
- No
- Approved uses
- Acute coronary syndrome and prevention after a heart attack, with aspirin
- Common side effects
- Bleeding, breathlessness, slow heart rate
- Evidence base
- PLATO, PEGASUS-TIMI 54
Uses and side effects are summarised in plain words from the approved prescribing information. This is not medical advice; check the full prescribing information. Sales and prescription figures are not shown because no official source publishes them by molecule. "Indian makers" lists companies that announced launches or approvals and is not a complete count.
One email a month. Reply to any email to unsubscribe. Privacy policy
Frequently asked questions
Which major medicines went off patent in India in 2026?
Semaglutide went off patent on 20 March 2026, and Natco, Sun Pharma, Dr Reddy's, Zydus, Glenmark and others launched generics. Zydus also launched Tishtha, a nivolumab biosimilar, on 22 January 2026 after a Delhi High Court ruling.
Which medicines in this tracker are under price control?
Teneligliptin, insulin glargine, trastuzumab, bedaquiline and sofosbuvir are in the National List of Essential Medicines 2022, so ceiling prices apply.
Which medicines here are still patent protected in India?
Tirzepatide, pembrolizumab and osimertinib. Indian companies are preparing biosimilars of pembrolizumab for when its patents end.
Download this tracker as Excel
Every row on this page in one spreadsheet, ready to filter and share with your team. Free for internal use.
Your download is starting. Thank you.
We use your details only to share related MRO research. See our privacy policy.
Related market reports
- India Drug Patent Expiry Calendar (free)
- Ruxolitinib market entry brief (USD 750)
- CDSCO Decoded (free, monthly)
- India Active Pharmaceutical Ingredients (API) Market
- India Biosimilars Market
- India Generic Drug Exports to the US Market
- India Key Starting Materials and Drug Intermediates Market
- India Pharmaceutical Excipients Market
- India Pharmaceutical Contract Manufacturing Market
Need the numbers behind this tracker?
We map patent timelines, competing makers and pricing for companies planning a launch in India.